Avant Immunotherapeutics Inc - Current report filing (8-K)
06 August 2008 - 4:52PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
PURSUANT
TO SECTION 13 OR 15(d)
OF
THE SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported):
August
6, 2008
AVANT
Immunotherapeutics, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
Commission file number
0-15006
|
13-3191702
|
(State or other jurisdiction
of incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
|
119 Fourth Avenue
Needham, Massachusetts 02494
|
|
|
(Address
of principal executive offices, including zip code)
|
|
(781) 433-0771
(
Registrant’s
telephone number, including area code)
(Former
name, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:
⃞
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
⃞
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
⃞
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
⃞
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
2.02 Results of Operations and Financial Condition.
On August 6, 2008, AVANT Immunotherapeutics, Inc. issued a press release
announcing its financial results for the second quarter of 2008. The
full text of the press release is furnished as Exhibit 99.1 hereto and
is incorporated by reference herein.
The information in this Item 2.02 of this Current Report on Form 8-K and
Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), or otherwise subject to the liabilities of that
Section, nor shall such information be deemed incorporated by reference
in any filing under the Securities Act of 1933, as amended (the
“Securities Act”), or the Exchange Act, except as shall be expressly set
forth by specific reference in such a filing.
Item
9.01 Financial Statements and Exhibits.
(d) Exhibits
99.1 Press Release of AVANT Immunotherapeutics, Inc., dated
August 6, 2008.
[Remainder of page left blank intentionally]
SIGNATURE
Pursuant to
the requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
AVANT Immunotherapeutics, Inc.
|
|
|
|
|
|
|
Dated:
|
August 6, 2008
|
By:
|
|
/s/ Avery W. Catlin
|
|
|
|
|
Avery W. Catlin
|
|
|
|
|
Senior Vice President and
|
|
|
|
|
Chief Financial Officer
|
Exhibit Index
|
|
99.1
|
Press Release of AVANT Immunotherapeutics, Inc., dated August 6,
2008.
|
Avant Immunotherapeutics (MM) (NASDAQ:AVAN)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Avant Immunotherapeutics (MM) (NASDAQ:AVAN)
Historical Stock Chart
Von Mai 2023 bis Mai 2024